NTRK1 and neoplasm: Further in vivo studies have confirmed the role of TrkA-dependent signaling in tumor development and progression (including metastasis), leading to the hypothesis that inhibiting the cascade of events produced by this neurotrophin could reduce tumorigenesis and consequently tumor hyperalgesia, thus improving patients’ quality of life.